TP53 and colorectal carcinoma: In accordance, our results showed no significant differences in the extents of reductions in aspartate levels between wildtype and mutant p53 CRC cells following IACS-010759 treatment, suggesting that targeting OXPHOS inhibits aspartate biosynthesis in CRC cells irrespective of their p53 statuses.